2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2249 Aponermin combined with carfilzomib-pomalidomide-dexamethasone (KPd) in relapsed/refractory multiple myeloma: Updated results from an expanded cohort with prolonged follow-up

Jing Chen, MD,PHD, Donghua He, MD,PHD2, Xiaoyan Han, MD,PHD3, Li Yang, MD,PHD4, Mingming Zhang, PhD5, He Huang, MD, PhD6, Juan Du, MD, PhD7, Aijun Liu, MD,PhD8, Lai Jin9, Zhen Cai, MD,PhD10
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Beijing Chao Yang Hospital, Beijing, China
9 Zhejiang Provincial People’s Hospital, Hangzhou, China
10 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background
Despite therapeutic advances in multiple myeloma (MM), managing heavily pretreated relapsed/refractory MM (RRMM) remains challenging. Aponermin (Apo), a recombinant circularly permuted human TNF-related apoptosis-inducing ligand (TRAIL), is a first-in-class death receptor 4/5 (DR4/5) agonist approved for RRMM. Preclinical evidence indicates that proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) sensitize myeloma cells to TRAIL-induced apoptosis, providing rationale for combining Apo with carfilzomib, pomalidomide, and dexamethasone (KPd). Following our initial 21-patient report at ASH 2025, we now present updated results from an expanded cohort of 37 RRMM patients treated with Apo-KPd in this ongoing prospective study (ChiCTR2500107812).
Aim
To report updated efficacy and safety from an expanded RRMM cohort treated with Apo-KPd, emphasizing high-risk cytogenetic subgroups, extramedullary disease (EMD), and patients relapsing after CAR-T or bispecific T-cell engager (BiTE) therapy.
Methods
Eligible patients met IMWG RRMM criteria with ≥3 prior lines or triple-class exposure (PI, IMiD, anti-CD38). Measurable disease and adequate organ function were required. Patients received 28-day cycles of Apo 10 mg/kg IV days 1–5; carfilzomib 20→27 mg/m² IV days 1–2, 8–9, and 15–16 (cycle 1: 20 mg/m² on days 1–2); pomalidomide 4 mg PO days 1–21; and dexamethasone 20 mg days 1–2, 8–9, and 15–16 until progression or unacceptable toxicity. Study design, eligibility, and dosing were identical to the preliminary 2025 analysis; only data cutoff and patient cohort were updated. Primary endpoint: overall response rate (ORR) per IMWG criteria.
Results
As of July 17, 2026, 37 evaluable patients (median age 63 years; 62.2% male) were enrolled, representing a 76% expansion from the prior 21-patient cohort with markedly extended follow-up (median 7.85 months versus 2 cycles in 2025). Baseline characteristics confirmed a heavily pretreated, poor-prognosis population: Durie-Salmon stage III in 67.6% (25/37), high-risk cytogenetics in 67.6% (25/37), and EMD in 70.3% (26/37). Patients received a median of 4 prior lines (range, 1–11), 59.1% had prior carfilzomib/pomalidomide, 84.1% were triple-class exposed, and 29.7% had received prior CAR-T or BiTE therapy.
Confirmed ORR was 78.4% (29/37; 95% CI, 62.8%–88.6%), with a ≥VGPR rate of 45.9% (17/37). Median time to response was 1.08 months (95% CI, 0.97–1.19), and median PFS was not yet reached. Subgroup analyses revealed consistent and deep responses across poor-prognosis subgroups. Comparable ORR/≥VGPR rates were observed between patients with >3 versus ≤3 prior lines (78.9%/42.1% vs. 77.8%/50.0%), triple-class exposed versus not (78.1%/43.8% vs. 80.0%/60.0%), and prior carfilzomib/pomalidomide exposure versus none (77.3%/40.9% vs. 80.0%/53.3%). In high-risk cytogenetics, ORR was 84.0% (compared to 57.1% in the prior 21-patient cohort), with a ≥VGPR rate of 48.0%. Notably, among 7 patients with TP53 deletion – an ultra-high-risk subgroup – the ORR was 85.7% (2 PR, 3 VGPR, and 1 CR), with 4 patients continuing treatment beyond 8 months. High and deep responses were also observed in patients with EMD (ORR 84.6%; ≥VGPR 57.7%), including extraosseous EMD (ORR 80.0%; ≥VGPR 66.7%). In the most heavily pretreated subpopulation with prior CAR-T or BiTE therapy (median 6 prior lines), Apo-KPd elicited an ORR of 81.8% and a ≥VGPR rate of 45.5%.
The safety profile remained clinically manageable with longer treatment exposure. Any-grade treatment-emergent adverse events (TEAEs) occurred in 70.3% (26/37). Grade 3–4 TEAEs were reported in 35.1% (13/37), including neutropenia (18.9%), tumor lysis syndrome (10.8%), pneumonia (8.1%), thrombocytopenia (8.1%), leukopenia (5.4%), anemia (2.7%), and hypertension (2.7%). No treatment-related mortality occurred.
Conclusion
This updated expanded-cohort analysis (n=37) substantiates and extends our initial ASH 2025 findings (n=21), demonstrating that Apo-KPd yields high response rates (ORR 78.4% vs. 66.7%; ≥VGPR 45.9% vs. 28.6%) with manageable safety in heavily pretreated RRMM. The regimen shows particularly noteworthy activity in historically refractory subgroups, including high-risk cytogenetics (ORR 84.0%, up from 57.1%), EMD (ORR 84.6%), TP53 deletion (ORR 85.7%), and CAR-T/BiTE-relapsed patients (ORR 81.8%), where conventional therapies frequently fail. These results support Apo-KPd as a promising salvage strategy in this high-need population.

Jing Chen, MD,PHD: No relevant conflicts of interest to declare.